Tekmira Pharmaceuticals (ABUS) - מקדם חוב לטווח ארוך להון

Arbutus Biopharma (ABUS) is modernizing its production facilities to expand the output of antiviral agents. The company is recognized as an expert in drug delivery methods, which has established its status as an authoritative developer in the eyes of major market players. However, dependence on patent disputes and capital shortages create serious threats, and this price chart with the 0.01 indicator confirms the high volatility of the business.

Arbutus Biopharma's dependence on licensing payments and patent disputes makes its financing structure critical for assessing sustainability. This ratio compares liabilities with a maturity of over one year to equity, measuring the level of debt leverage and insolvency risk, which allows the long-term debt-to-equity trend to determine the balance between aggressive growth and financial stability.